BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
基本信息
- 批准号:8904217
- 负责人:
- 金额:$ 97.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-18 至 2017-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdultAffectBMX geneBlood - brain barrier anatomyBrainBrain NeoplasmsCancer PatientChemistryClinical TrialsCognitionCranial IrradiationDeteriorationDiagnosisDiffusion Magnetic Resonance ImagingDisease ProgressionDoseDrug FormulationsDrug KineticsExcisionGlioblastomaGliomaGoalsHairHippocampus (Brain)HumanImpaired cognitionImpairmentInvestmentsJoint VenturesMagnetic Resonance ImagingMalignant NeoplasmsManganeseMaximum Tolerated DoseMetalloporphyrinsNervous System PhysiologyNervous system structureNeuraxisNewly DiagnosedNormal tissue morphologyNuclearOperative Surgical ProceduresOutcomeOxidation-ReductionOxidative StressPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePhasePhase I Clinical TrialsPhase II Clinical TrialsPrimary Brain NeoplasmsProgression-Free SurvivalsRadiationRadiation induced damageRadiation therapyRadiation-Sensitizing AgentsRadioRandomizedReactive Oxygen SpeciesResistanceSafetySeriesSmall Business Innovation Research GrantStem cellsStressTestingTherapeuticTherapeutic AgentsToxicologyTreatment ProtocolsUp-Regulationbasebrain tissuecancer diagnosischemotherapydrug qualityhealth related quality of lifehuman subjectimprovedkillingsneurotoxicitynext generationopen labelpreclinical safetypreclinical studypreventprimary outcomepublic health relevanceresponsescale upsecondary outcomestability testingstandard of caretemozolomidetranscription factortreatment responsetumorwhite matterwhite matter damage
项目摘要
DESCRIPTION (provided by applicant): Phase 1 and Phase 2 clinical trials of a new class of redox-active pharmaceutical are proposed in high-grade glioma (WHO grade III and IV). This project will test a compound that crosses the blood-brain barrier and which prevents hippocampal stem cell loss and white matter degradation following radiation therapy (RT). The compound also inhibits tumor regrowth following RT and thus has the dual impact of protecting normal tissues while improving tumor treatment responses. This drug is both neuroprotective against RT and a radio sensitizer that is expected to enhance inhibition of glioblastoma by RT. Primary brain tumors represent 1% of all diagnosed cancers. Even though these tumors represent a rare malignancy, high-grade gliomas are aggressive and lethal and are associated with severe disabling central nervous system involvement. Cognition and neurological function are compromised at diagnosis and during treatment. The standard of care for newly diagnosed high-grade gliomas involves surgical resection, followed by RT with concurrent temozolomide (TMZ). Despite aggressive treatment, nearly all patients with the most common form of adult primary brain tumor, glioblastoma (WHO grade IV), die of disease progression; median survival is 9-15 months after diagnosis. Most high-grade gliomas are resistant to current available therapies. Thus, a major requirement for the next generation therapy of primary brain tumors requires more effective tumor control and protection against the neurotoxicity. The objective of this proposed project is to test the hypothesis that a new class of redox-active metalloporphyrins is an effective radio protector and tumor sensitizer in brain tissue. The specific aims are to: 1) perform a Phase 1 clinical trial of this new drug in combination with standard RT and TMZ in newly diagnosed high-grade glioma patients, and 2) perform a randomized open-label Phase 2 clinical trial of the new drug in combination with standard RT and TMZ versus standard RT and TMZ alone in patients with newly diagnosed high-grade glioma patients. The primary outcome is protection/improvement of cognition. This new class of drug has the potential to protect against deterioration of cognition and improve health-related quality of life in high-grade glioma patients
undergoing RT and chemotherapy, while also enhancing patient survival.
描述(申请人提供):一种新型氧化还原活性药物的1期和2期临床试验计划用于治疗高级别胶质瘤(WHO分级为III级和IV级)。该项目将测试一种化合物,这种化合物可以穿越血脑屏障,防止放射治疗(RT)后海马区干细胞丢失和白质降解。该化合物还可以抑制放疗后的肿瘤再生长,因此具有保护正常组织和改善肿瘤治疗反应的双重作用。这种药物既对RT具有神经保护作用,又是一种放射增敏剂,有望通过RT加强对胶质母细胞瘤的抑制。原发脑瘤占所有确诊癌症的1%。尽管这些肿瘤是一种罕见的恶性肿瘤,但高级别胶质瘤具有侵袭性和致命性,并与严重致残的中枢神经系统相关。认知和神经功能在诊断和治疗过程中受到损害。对新诊断的高级别胶质瘤的标准治疗包括手术切除,然后同步应用替莫唑胺(TMZ)进行放疗。尽管进行了积极的治疗,但几乎所有患有最常见的成人原发脑肿瘤--胶质母细胞瘤(WHO IV级)的患者都死于疾病进展;中位生存期为确诊后9-15个月。大多数高级别胶质瘤对目前可用的治疗方法都有抵抗力。因此,下一代治疗原发脑肿瘤的一个主要要求是更有效地控制肿瘤并保护其免受神经毒性。这项提议的项目的目的是检验一种新的氧化还原活性金属卟啉是脑组织中有效的辐射保护剂和肿瘤增敏剂的假设。具体目标是:1)在新诊断的高级别胶质瘤患者中进行该新药联合标准RT和TMZ的第一阶段临床试验,以及2)在新诊断的高级别胶质瘤患者中进行该新药联合标准RT和TMZ与单独使用标准RT和TMZ的随机开放标签第二阶段临床试验。主要结果是保护/改善认知。这种新型药物有可能防止认知能力的恶化,并改善高级别胶质瘤患者与健康相关的生活质量。
接受放射治疗和化疗,同时也提高了患者的存活率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James D Crapo其他文献
James D Crapo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James D Crapo', 18)}}的其他基金
COPD(GENE): TASK B: "STEWARDSHIP OF BIOSPECIMEN AND DATA REPOSITORIES"
COPD(基因):任务 B:“生物样本和数据存储库的管理”
- 批准号:
10974167 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) TASK A: STUDY VISIT 4, COLLECTION OF COPDGENE STUDY DATA ANDBIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY
COPD 的遗传流行病学(COPD 基因) 任务 A:研究访问 4、收集 COPDGENE 研究数据和生物样本以及 COPDGENE 研究的监督
- 批准号:
10974166 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
- 批准号:
10603182 - 财政年份:2015
- 资助金额:
$ 97.64万 - 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
- 批准号:
9145170 - 财政年份:2015
- 资助金额:
$ 97.64万 - 项目类别:
BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas
BMX-001 作为治疗高级别胶质瘤的治疗剂
- 批准号:
10170294 - 财政年份:2015
- 资助金额:
$ 97.64万 - 项目类别:
Building Consensus on Qualitative Chest CT-based Subphenotypes for COPD
就慢性阻塞性肺病基于胸部 CT 的定性亚表型建立共识
- 批准号:
7915158 - 财政年份:2010
- 资助金额:
$ 97.64万 - 项目类别:
TREATMENT OF BPD USING MIMETICS OF SUPEROXIDE DISMUTASE
使用超氧化物歧化酶模拟物治疗 BPD
- 批准号:
7716049 - 财政年份:2008
- 资助金额:
$ 97.64万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 97.64万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 97.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)